



for safe, timely and affordable patient-centric innovation
How off-patent medicines can improve the equity and quality of cancer care
After several months of crisis, we can discern some of the key lessons learned from COVID-19 for the future of pharmaceutical policy in Europe.
OPEN LETTER Time for a new medicine security contract for Europe
Read more